The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
Open accessAbstract
PURPOSE OF REVIEW: Rifaximin is gaining attention for its potential activity in a multitude of gastrointestinal diseases. We review the unique pharmaceutical properties of this antibiotic and the published evidence in the literature regarding the use of rifaximin for different gastrointestinal disorders. RECENT FINDINGS: Rifaximin is a gastrointestinal-selective antibiotic with a broad spectrum of antimicrobial activity, an excellent safety profile, minimal drug interactions, and negligible impact on the intestinal microbiome. Rifaximin is currently approved in the United States for the treatment of travelers' diarrhea caused by noninvasive diarrheagenic Escherichia coli and is approved in more than 30 other countries for a variety of gastrointestinal disorders. Considerable research with this medication has been conducted for the treatment and prevention of travelers' diarrhea, the treatment of portal systemic encephalopathy, Clostridium difficile infection, small bowel intestinal overgrowth, irritable bowel syndrome, inflammatory bowel disease, pouchitis, and colonic diverticular disease. SUMMARY: Rifaximin is effective for the treatment of travelers' diarrhea and can be considered as the treatment of choice for uncomplicated travelers' diarrhea. When invasive travelers' diarrhea pathogens are suspected, an alternative antibiotic should be administered. Rifaximin appears promising as a chemoprophylaxis for travelers' diarrhea and as a treatment of portal systemic encephalopathy. This antibiotic may be effective for other gastrointestinal diseases, but more well designed clinical studies are needed to confirm its efficacy for these off-label indications. Future studies will determine whether the development of significant bacterial resistance will limit rifaximin use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rifaximin is a nonabsorbable antibiotic with broad-spectrum antimicrobial activity and an excellent safety profile113 that was initially approved for the treatment of traveller’s diarrhoea but is increasingly used for the prevention of hepatic encephalopathy99.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microbial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927
Diverticular Disease of the Colon
Fox, J. M., & Stollman, N. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00117-7 · Cited by 822
Pimentel, M., Chow, E. J., & Lin, H. C. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07234.x · Cited by 670
The specific inhibition of the DNA-directed RNA synthesis by rifamycin
Hartmann, G. R., Honikel, K. O., Knüsel, F., & Nüesch, J. (1967) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(67)90147-5 · Cited by 519
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Diverticular Disease of the Colon, a 20th Century Problem
Painter, N. S., & Burkitt, D. P. (1975) · Clinics in Gastroenterology · doi:10.1016/s0300-5089(21)00094-8 · Cited by 412
A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute Pouchitis
Shen, B., Achkar, J., Lashner, B. A., Ormsby, A., Remzi, F. H., Brzezinski, A., Bevins, C. L., Bambrick, M. L., Seidner, D. L., & Fazio, V. W. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200111000-00004 · Cited by 349
Sharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Johnson, S., Schriever, C. A., Galang, M. A., Kelly, C. P., & Gerding, D. N. (2007) · Clinical Infectious Diseases · doi:10.1086/511870 · Cited by 310
Research works printed but not linked: 9
- Descombe, 1994, Int J Clin Pharmacol Res, 14, 51
- Pedretti, 1991, Ital J Gastroenterol, 23, 175
- Boero, 1990, Microbiologia Medica, 5, 74
- Esposito, 2007, World J Gastroenterol, 13, 6016, 10.3748/wjg.v13.45.6016 · DOI · Paper page
- Thompson, 1999, Gut, 45, II80
- Majewski, 2007, Adv Med Sci, 52, 139
- Pimentel, 2003, Am J Gastroenterol, 98, 412
- Prantera, 1996, Am J Gastroenterol, 91, 328
- Nasmyth, 1989, Gastroenterology, 96, 817, 10.1016/0016-5085(89)90907-4 · DOI
Cited by
Sorted by citations
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
“Neomycin was the original choice(184) 185 although interest is now focused on a non-absorbed derivative of rifampicin called rifaximin.(186) There are three fully-published, double blind, placebo controlled trials of rifaximin in FBD and the data suggest an improvement in symptoms, especially bloating and flatulence f…”
BackgroundBacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.024 · Cited by 906
“Rifaximin, an antibiotic with broad-spectrum antimicrobial activity that eliminates intestinal flora non-selectively [156], has been suggested as a potential alternative to norfloxacin in the prophylaxis of bacterial infections in cirrhosis.”
BackgroundSynthesis of imidazo[1,2-a]pyridines: a decade update
Bagdi, A. K., Santra, S., Monir, K., & Hajra, A. (2014) · Chemical Communications · doi:10.1039/c4cc08495k · Cited by 642
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Small intestinal bacterial overgrowth syndrome
Bures, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.2978 · Cited by 620
Metadata
- Authors
- Koo, H. L., & DuPont, H. L.
- Affiliations
- Baylor College of Medicine (US)
- Baylor St. Luke's Medical Center (US)
- Corresponding author
- Koo, Hoonmo L
- ORCID
- DuPont, Herbert L
- Venue
- Current Opinion in Gastroenterology
- Published
- 2010-01
- Volume
- 26
- Issue
- 1
- Pages
- 17-25
- ISSN
- 0267-1379 (ISSN-L)
- PMC
- PMC4737517
- OpenAlex
- W2121076704
- Cited by
- 189
- References
- 76
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 13 · 2023: 8 · 2022: 15 · 2021: 13 · 2020: 11 · 2019: 9 · 2018: 10 · 2017: 7 · 2016: 10 · 2015: 12 · 2014: 11 · 2013: 10 · 2012: 18
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Opinion in Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Houston
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK084513)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Keywords
- rifaximin, traveler's diarrhea, portal-systemic encephalopathy, Clostridium difficile infection, small intestinal bacterial overgrowth, irritable bowel syndrome, inflammatory bowel disease, pouchitis, colonic diverticular disease, chemoprophylaxis, gut microbiota, drug resistance
- MeSH terms
- Rifaximin, Anti-Infective Agents, Bacterial Infections, Dose-Response Relationship, Drug, Drug Administration Schedule, Dysentery, Female, Follow-Up Studies, Gastroenteritis, Humans, Male, Rifamycins, Travel, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
